Background: This study reports the infection rate, location of infection and pathogen causing bacterial, fungal or viral infections in intestine transplant recipients at a pediatric transplant center. Methods: Records from a pediatric center were reviewed for patients receiving an intestine transplant. Positive cultures and pathology reports were used to diagnose bacterial, fungal and viral infections and also to determine location and infectious agent. Risk for infection was assessed based on liver or colon inclusion, and immunosuppression induction, as part of the intestine transplant. Results: During the study period, 52 intestine transplants were performed on 46 patients. Bacterial, fungal and viral infection rates were 90%, 25% and 75%, respectively. Enterococcus spp. (non-vancomycin-resistant enterococci) were the most common pathogens and were isolated from 52% of patients. Non-vancomycin-resistant enterococci was present in 12% of transplant recipients. Candida spp. were the most common fungal pathogens (23% of patients). Respiratory viral infections were common (44%), and Cytomegalovirus infection rate was 17%. Common sites of infection were bloodstream, urinary and upper respiratory tract. Colon and liver inclusion in the transplant graft was not associated with increased risk of infection, nor was addition of rituximab to the immunosuppression induction protocol. Conclusions: Postintestine transplant infections are ubiquitous in the pediatric population, including high rates of infection from bacterial, viral and fungal sources. Inclusion of the liver and/or colon as a component of the transplant graft did not appear to greatly impact the infectious risk. Adding rituximab to the immunosuppression induction protocol did not impact on infectious risk.
I
ntestine transplantation has become a potentially curative procedure for patients with intestine failure who have failed total parenteral nutrition or who are poor candidates for longterm total parenteral nutrition. 1 It is also a therapeutic option for patients who have diffuse portomesenteric thrombosis, unresectable benign intra-abdominal tumors and other intraabdominal pathologies (frozen abdomen and long segment Hirschsprung's). 2, 3 Transplant options for pediatric patients include isolated intestine (IT) and multivisceral (MVT; liver, stomach, pancreas, intestine) transplant. 4, 5 The proximal large intestine may also be included in the composite graft to preserve the ileocecal valve, to reduce the risk of dehydration by increasing water absorption and to minimize stooling. Intestine transplant can be a life-saving procedure, and in recent years, outcomes have improved. However, intestine transplant continues to be associated with serious and life-threatening posttransplant complications. 6 Infection is the most prevalent posttransplant complication for all solid organ transplants and is a leading cause of death and graft loss in intestine transplant recipients. 4 Patients are at the highest risk for bacterial, fungal and viral infections in the first year posttransplant due to the invasive nature of the procedure and the requirement for high doses of immunosuppressive agents. The bloodstream is the most worrisome site of infection because it is associated with high morbidity and can lead to sepsis which is the primary cause of death in intestine transplant patients. 7 The incidence of bloodstream infections (BSIs: bacterial and fungal) has been reported to be as high as 69% in the pediatric intestine transplant population. Reported risk factors for the development of BSI include liver inclusion, <18 years of age and bilirubin >5 mg/dL at the time of transplant. 8, 9 Infections caused by fungi are not as common as bacterial infections in intestine transplant recipients but are responsible for 31% of all infection-related deaths. 4 Aspergillus and Candida are the most prominent fungal species infecting pediatric intestine transplant patients. The majority of fungal infections in this population is caused by Candida spp. with Candida albicans being the most commonly isolated species. 10 Viral infections are also frequently found in pediatric intestine transplant patients and can be caused by reactivation of a latent infection or by de novo infection. Additionally, viral infections have been associated with serious complications such as posttransplant lymphoproliferative disorder and acute cellular rejection, among others. 11, 12 This study reports bacterial, fungal and viral infection rates at an active pediatric intestine transplant center in the first year posttransplant. Incidence of infection is reported by anatomic site and individual pathogenic species. Risk for infection is assessed based on liver and large intestine inclusion, as well as an examination of potential risk factors for the development of BSI.
METHODS
A retrospective chart review was conducted for all patients receiving an intestine transplant at a single pediatric transplant center from 2003 to 2015. Intestine transplantation occurred as either an IT or MVT. Additionally, a subset of patients received the proximal large intestine from the donor as part of the intestine graft. All patients were included in the final analysis regardless of outcome.
MVT and IT protocols employed at our center have been previously described. 3, 13, 14 Neither the donor nor the recipient received mechanical or pharmacologic decontamination of the intestine as part of intestine transplant process. 15 To ensure that an IT graft was not exposed to an intestine decontamination solution when the pancreas was procured by another center, the 17 Serum target levels for tacrolimus were 10-12 ng/dL in the first 6 months posttransplant and then were decreased to 7-8 ng/dL thereafter. Patients with any history of rejection were maintained on the higher target level during 1-year posttransplant, before the target was lowered. Also, those patients experiencing any episode of rejection were maintained on long-term, low-dose prednisone (5-10 mg/d). Tacrolimus target levels were consistently maintained at higher target values, for a longer period, for patients receiving IT transplant. MVT transplant recipients have a much lower rate of rejection and are more aggressively weaned to lower targets. In the majority of cases, prophylactic empiric antibiotic use (piperacillin/tazobactam or cefepime) was continued for the first 48 hours posttransplant. If there was considerable gross contamination at the time of surgery, antibiotic prophylaxis was continued for up to 7 days. Antifungal prophylaxis consisted of a one-time dose of 100-400 mg of fluconazole before surgery with 25-100 mg taken daily for the first year posttransplant (dosing per patient age and size). Daily trimethoprim-sulfamethoxazole is used for Pneumocystis jirovecii pneumonia prophylaxis and is taken indefinitely. Prophylactic treatment for viral infections included intravenous ganciclovir and Cytomegalovirus (CMV) immune globulin (cytogam) in the early posttransplant period. When the patient was tolerating enteral medications, the ganciclovir was changed to enteral valganciclovir (usually within 2-3 weeks of the intestine transplant). Enteral valganciclovir and monthly cytogam were continued up to 1-year posttransplant. At that time, they were both withdrawn if there had been no episodes of CMV infection. Monitoring for signs of infection was performed at least daily in the early posttransplant period and included measurement of the white blood cell count and routine vital signs. If leukocytosis was present, or a fever detected, blood and urine samples were sent for culture. Sputum cultures were not routinely assessed but were sent in cases of respiratory symptoms such as cough, shortness of breath, infiltrate on chest radiograph or need for supplemental oxygen. Additionally, all fluids drained from identified abnormal fluid collections or body cavities were sent for culture. Treatment of infections consisted of antibiotic therapy for 7-14 days, or until patients were asymptomatic, with individual pathogen sensitivities governing antibiotic selection.
Positive cultures and pathology reports were reviewed to determine the presence of an infection, the organism causing the infection and the anatomic location of infection. All data collected in the first year posttransplant were utilized for the analysis presented in this article. All postoperative positive cultures were included regardless of location or infectious organism. BSIs were not limited to those caused by an indwelling catheter. Active infections at the time of transplant were excluded from this study.
Standard statistical techniques, which included χ 2 analysis for categorical variables and analysis of variance testing for continuous variables, were performed using the Statistical Package for the Social Sciences (IBM SPSS Statistics 24; IBM Corporation, Armonk, NY). For subgroup analysis, patients were grouped based on liver or large intestine inclusion as part of the small intestine inclusive graft. Evaluation of potential risk factors for BSI included transplant of the liver or large intestine with the intestine allograft, age (≤2 or 2-18 years of age), gender and race (white or non-white). Although a P value of 0.05 is a standard, often used to determine statistical significance, there were a large number of individual tests performed in analysis of data for this cohort. Therefore, given the high number of tests performed and the possible interrelatedness of the tests, an accurate P value for determining significance may be as low as 0.01. However, this is primarily a descriptive clinical article. The P values will be reported as calculated, and the reader may determine the clinical importance of these findings. The institutional review board at the Indiana University School of Medicine reviewed and approved the retrospective analysis of these data from the transplant database.
RESULTS
There were 46 pediatric patients who underwent 52 intestine transplants during the study period. A total of 34 patients (65%) received a MVT, while 18 (35%) received an IT. The proximal large intestine was transplanted with the small bowel in 6 patients (12%). Median age of recipients was 1.6 years (range, 0.3-18 years). Donors had a median age of 1.5 years with trauma being the leading cause of death among them. For immunosuppression induction, 75% of patients received both antithymocyte globulin and rituximab (Table 1) .
Bacterial infections were the most common type of infection and occurred in 90% of patients. The most common sites of bacterial infection were the urinary tract (73%) and bloodstream (75%). Pulmonary and wound infections were not as prevalent and occurred in less than 30% of patients, while abscesses developed in 4% of intestine recipients. Clostridium difficile infections were present in 23% of patients and were less common in MVT (17%) than in IT (27%) (P = 0.43) ( Table 2) . Gram-positive infections were primarily caused by non-vancomycin-resistant enterococci (VRE) species (52%), coagulase-negative Staphylococcus (48%) and Streptococcus spp. (23%). VRE and methicillin-resistant Staphylococcus aureus (MRSA) were isolated from 12% and 4% of patients, respectively. Other Gram-positive pathogens including methicillin-susceptible S. aureus, Bacillus spp., Lactobacillus spp. and Corynebacterium spp. were all isolated in 10% or less of patients. There were no Clostridium infections outside of (Table 3) . Liver inclusion had no significant effect on bacterial strain or site of infection; transplant of the large intestine was observed to be protective against coagulase-negative Staphylococcus (P = 0.01) and BSIs (P = 0.03) ( Tables 2 and 3 ).
Fungal pathogens were isolated from 25% of patients. Similar to bacterial infections, the urinary tract (10%) and bloodstream (10%) were the most common sites of fungal infection. Only 2 patients (4%) developed a pulmonary fungal infection, 1 patient (2%) developed a fungal abscess and a single patient (2%) had a fungal wound infection. Candida spp. were the most commonly isolated fungal pathogen and were found in 23% of patients. C. albicans was isolated from 12% of patients and found in half of all Candida-infected patients. Infections caused by other Candida spp. (Candida krusei, Candida glabrata and Candida parapsilosis) were less common. Aspergillus-related infections were rare and only seen in a single patient (2%) ( Tables 2  and 4 ). Although not statistically significant, only 1 patient who received a large intestine as part of the intestine transplant developed a fungal infection.
Viral infections were observed in 75% of pediatric intestine recipients. Gastrointestinal tract and upper respiratory tract viral infections were common and occurred in 52% and 39% of patients, respectively. Only 12% of patients developed lower respiratory viral infections, while viremia was seen in 31% of recipients. CMV infected 9 patients (17%, active viremia) and was tissue invasive in 4 (8%). Adenovirus and Rhinovirus were the most frequently isolated viruses and were found in 29% and 27% of patients, respectively. All other cultured viruses [Epstein-Barr virus (EBV), Rotavirus, Norovirus, Herpesvirus 6 and parainfluenza), with the exception of respiratory syncytial virus (6%), were isolated from at least 10% of patients. Large intestine inclusion was associated with an increased risk for infection by Herpesvirus 6 (P < 0.01) and upper respiratory infections (P = 0.03) ( Tables 2 and 4) .
BSIs (bacterial or fungal) developed in 77% of patients, with a median time of 38 days to the first infection. Age, race, gender, liver inclusion and rituximab induction had no significant impact on BSI development, whereas patients receiving a large intestine graft were at a lower risk for developing a BSI (P = 0.02). Of the covariates evaluated, only rituximab induction had significant impact on median time to first BSI (43 days with rituximab vs. 16 days without, P = 0.02) ( Table 5) . 
DISCUSSION
Infection is the most common posttransplant complication and the leading cause of morbidity and mortality in pediatric intestine transplant recipients. The high incidence of infection could be due to the invasiveness and nonsterile nature of the transplant procedure, or due to the need for increased levels of immunosuppression in comparison with other solid organ transplants. Identification of commonly infecting pathogens and risk factors for the development of infections is needed to develop therapeutic plans to mitigate the harmful effects of infection in this high-risk population.
Bacterial infections are the most common type of infection in intestine transplant recipients. 4 Infection rates have been reported to be as high as 93% in intestine transplantation that is similar to the 90% rate reported in this cohort. 18 In an attempt to prevent Gram-negative and fungal infections, some centers use an intestine decontamination solution before or during transplantation of the small intestine graft. However, the efficacy of its use has yet to be definitively shown and may provide no significant benefit. 15, 19 Certainly, use of this therapy disrupts the native microbiome that may negatively impact on the function of the graft.
Antibiotic-resistant bacteria are increasing in prevalence and pose unique challenges in solid organ transplantation. 20 In adult patients, the incidence of VRE and MRSA has been reported to be as high as 75% and 100%, respectively. 21 While this rate is alarming, in pediatric patients, the incidence is much lower, with 36% of S. aureus infection being methicillin resistant and 21% of enterococci infections being vancomycin resistant. 8, 22 The present study finds similar results with 29% of S. aureus infection being MRSA and 18% of enterococci infections being VRE. The overall incidence of MRSA and VRE was relatively low at 4% and 12%, respectively. Although the resistant rates of VRE and MRSA in the pediatric population are lower than that seen in adults, these pathogens are still associated with substantial morbidity and have limited treatment options. Prevention protocols and novel treatments need to be developed and implemented to mitigate the deleterious effects of these pathogens.
Additionally, fungemia has been associated with antibiotic use in intestine transplantation, further highlighting the need for infection prevention. 23 In this study, the incidence of fungal infections was 25% and the 2 most prominent genera causing fungal infections were Candida and Aspergillus that is congruent with previously published data. Additionally, this study and previous data have shown C. albicans to be the most common fungal species isolated from pediatric intestine transplant recipients. Aspergillus infections are associated with significantly shorter survival times, and with higher morbidity, when compared with Candida infections. 10 Although Aspergillus infections are associated with a higher mortality, disseminated infections in intestine transplant patients have been treated successfully. 24 Viral infections caused by CMV, Adenovirus and respiratory viruses were the most commonly isolated viruses in this cohort of patients. CMV is associated with increased mortality, infection and rejection episodes in intestine transplantation. 12 Adenovirus is associated with respiratory or gastrointestinal infections and can also be a contributing factor in graft rejection and patient mortality. 25 Respiratory tract viral infections are frequently seen in solid organ transplant recipients. Tran et al 26 reported that 83% of pediatric patients with respiratory symptomatology were positive for at least 1 virus. While respiratory viruses were common, only respiratory syncytial virus and Adenovirus were associated with morbidity. EBV, which had 10% rate of infection in this study, is another virus associated with morbidity in intestine transplant recipients with the EBV genome being found in 90% of patients who develop posttransplant lymphoproliferative disorder.
11
Previously published risk factors for the development of BSI in intestine transplantation include liver inclusion with the intestine graft, age (<18 years of age) and bilirubin >5 mg/dL at the time of transplant. In contrast to previous studies, this study found no correlation between liver inclusion and recipient age and the development of BSI. However, inclusion of the large intestine was associated with a reduced risk of BSI development. These findings suggest that more research is needed to identify risk factors and predictors of BSI development that will enable clinicians to better care for this high-risk population. This is a small population, such that the results are more descriptive of this unique population rather than a statistically driven resource for protocol development.
In conclusion, this study reports the 1-year incidence of infection in the high-risk pediatric intestine transplant population, with results stratified by anatomic location and pathogen type (including bacterial, fungal, viral and individual pathogenic species). The high rate of infection and associated morbidity among this patient population informs the need for better methods of 
